SynthesisSleep & breathing = Schlaf & Atmung2026
Investigating the effect of valsartan/sacubitril on sleep parameters of patients with sleep apnea: systematic review and meta-analysis.
Synthesis in Sleep & breathing = Schlaf & Atmung, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesSleep apnea, often linked to heart failure, may benefit from sacubitril/valsartan (SV), a promising treatment shown to improve sleep quality and variables. This review and meta-analysis assess the sleep-related effects of SV in patients with sleep apnea.
methodsThis systematic review and meta-analysis involved a search of several databases, including Embase, Web of Science, PubMed/Medline, Cochrane, and Scopus, conducted through October 2024. The results, comparing post-intervention effects of valsartan/sacubitril versus pre-intervention values, were evaluated across different groups: Overall, Central, and Obstructive. The analysis focused on several sleep parameters, including SpO2 < 90% (%), mean SpO2 (%), OAI (Obstructive Apnea Index, events/h), CAI (Central Apnea Index, events/h), and AHI (Apnea-Hypopnea Index, events/h).
findingsSix studies, including 12 records from non-controlled intervention studies, were analyzed. Significant reductions in AHI were observed across all groups post-intervention, with the most notable decrease in the Obstructive group (SMD = -0.74, 95% CI: -1.15 to -0.33, P = 0.004). A decrease was also seen in the Overall group (SMD = -0.48, 95% CI: -0.62 to -0.33, P < 0.001) and the Central group (SMD = -0.47, 95% CI: -0.78 to -0.16, P = 0.003). Additionally, CAI values decreased in all groups, while OAI and mean SpO2 values increased.
conclusionThe results of this study suggest that treatment with SV medication in patients suffering from sleep apnea typically results in improvements in sleep parameters like CAI and AHI, leading to a notable improvement in their overall sleep quality. CLINICAL TRIAL REGISTRATION NUMBER: Not required
Indexed as
Identifiers
41731200What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.